IP Library › Granted Patent US 9,707,245
Granted Patent B2
US 9,707,245 · App. 15/357,932 · Granted Jul 18, 2017

Neridronic acid for treating complex regional pain syndrome

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,707,245
App. No.
15/357,932
Granted
Jul 18, 2017
Kind
B2
Abstract

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.

Claims (30)

1. A method of treating pain associated with complex regional pain syndrome (CRPS) comprising administering neridronic acid to a human being with CRPS, wherein bone fracture was a predisposing event for CRPS, and wherein the neridronic acid is in a salt or an acid form.

2. The method of claim 1 , wherein the CRPS is CRPS type I.

3. The method of claim 1 , wherein the neridronic acid is in a salt form.

4. The method of claim 1 , wherein the neridronic acid is administered intravenously.

5. The method of claim 1 , wherein the neridronic acid is administered orally.

6. The method of claim 5 , wherein a total of about 50 mg to about 500 mg of the neridronic acid is administered daily.

7. The method of claim 5 , wherein a total of about 100 mg to about 500 mg of the neridronic acid is administered daily.

8. The method of claim 5 , wherein a total of about 150 mg to about 300 mg of the neridronic acid is administered daily.

9. The method of claim 1 , wherein the neridronic acid is administered parenterally.

10. The method of claim 9 , wherein a total of about 5 mg to about 500 mg of the neridronic acid is administered within one month.

11. The method of claim 9 , wherein a total of about 5 mg to about 200 mg of the neridronic acid is administered within one month.

12. The method of claim 9 , wherein each dose contains about 10 mg to about 150 mg of the neridronic acid.

13. The method of claim 9 , wherein a total of about 100 mg to about 300 mg of the neridronic acid is administered within one month.

14. The method of claim 1 , wherein a total of about 100 mg to about 600 mg of the neridronic acid is administered.

15. The method of claim 1 , wherein a total of about 100 mg to about 300 mg of the neridronic acid is administered.

16. The method of claim 4 , wherein each dose contains about 10 mg to about 150 mg of the neridronic acid.

17. The method of claim 4 , wherein each dose contains about 100 mg of the neridronic acid.

18. The method of claim 17 , wherein the neridronic acid is administered at least four times.

19. The method of claim 4 , wherein each dose contains about 50 mg to about 65 mg of the neridronic acid.

20. The method of claim 19 , wherein the neridronic acid is administered about every three days.

21. The method of claim 5 , wherein each dose contains about 100 mg of the neridronic acid.

22. The method of claim 3 , wherein each dose contains an equivalent of about 50 mg to about 60 mg of the neridronic acid.

23. The method of claim 1 , wherein the neridronic acid is administered about once daily to about once weekly.

24. The method of claim 1 , wherein the neridronic acid is administered in a single or in divided doses.

25. The method of claim 21 , wherein about four doses of about 100 mg of the neridronic acid are administered.

26. The method of claim 1 , wherein the neridronic acid is administered weekly for about four to about six weeks.

27. The method of claim 1 , wherein the human being is at least 18 years of age.

28. The method of claim 27 , wherein the human being is at least 40 years of age.

29. The method of claim 27 , wherein the human being has a baseline pain intensity score of at least 4 on the 0-10 Numeric Rating Scale.

30. The method of claim 1 , wherein the CRPS is CRPS type II.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2017
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 041540/0772 →